DICLOXACILLIN SODIUM | A062286 | TEVA PHARMACEUTICALS USA INC
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Citizen Petition from Aurobindo Pharma USA, Inc. FDA-2020-P-1427 · 3 docket documents Aurobindo Pharma USA, Inc. filed this citizen petition under Section 505(j) of the Federal Food, Drug, and Cosmetic Act requesting that the FDA designate Dicloxacillin Sodium Capsules 500 mg (ANDA #062286) of Teva Pharmaceuticals USA Inc. as a new reference standard for in vivo bioequivalence studie | Other | 2020-05-28 | Withdrawn | Aurobindo Pharma USA, Inc. |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$1.06
per ea
Lowest NADAC/Unit
$0.5749
per ea
Brand NDCs
0
Generic NDCs
2
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 00093312501DICLOXACILLIN 500 MG CAPSULE | $1.06 | EA | Generic | — | 2026-06-17 |
| 00093312301DICLOXACILLIN 250 MG CAPSULE | $0.5749 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.